UPDATE: Piper Jaffray Initiates Coverage on Repros Therapeutics on a Cleaner Approach to Male Hypogonadism

In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Repros Therapeutics (NASDAQ: RPRX ) with an Overweight rating and $26.00 price target. In the report, Piper Jaffray noted, “We are initiating coverage of RPRX with an Overweight rating and $26 PT, representing 85% upside from